A Randomized Study Comparing Subtotal vs Total Hysterectomy Long Term Outcomes

NCT ID: NCT06802198

Last Updated: 2025-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-01

Study Completion Date

2030-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomized clinical trial is to assess the outcomes of total laparoscopic hysterectomy vs subtotal laparoscopic hysterectomy + mini-laparotomy for uterine extraction for benign gynecological conditions in terms of change in quality of life at 36 months after surgery and patient's impression of improvement. The secondary objectives of the study are to assess any differences in terms of peri and postoperative outcomes (postoperative pain, blood loss, hospital stay, intraoperative or short and long-term postoperative complications, long term urinary, bowel and pelvic floor symptoms, prevalence of vaginal cuff dehiscence).

Participants will fill the following questionnaires pre-operatively and at the follow up:

* Short Form 36 (SF36),
* Euro Quality of life 5D-3L (EQ 5D-3L)
* Female Sexual Function Index (FSFI)
* Patient Global Impression of Improvement (PGI-I) only during the follow-up period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fibroid Uterus Metrorrhagia Adenomyosis Benign Gynecologic Neoplasm Endometriosis Abnormal Uterine Bleeding

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients undergoing total hysterectomy

Total hysterectomy involves the complete removal of the uterus including the cervix

Group Type ACTIVE_COMPARATOR

total hysterectomy

Intervention Type PROCEDURE

Total hysterectomy (TH) involves the complete removal of the uterus including the cervix

patients undergoing subtotal hysterectomy

Subtotal hysterectomy involves the removal of the upper part of the uterus preserving the cervix

Group Type EXPERIMENTAL

subtotal hysterectomy

Intervention Type PROCEDURE

subtotal hysterectomy (STH) preserves the cervix while removing the upper part of the uterus

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

total hysterectomy

Total hysterectomy (TH) involves the complete removal of the uterus including the cervix

Intervention Type PROCEDURE

subtotal hysterectomy

subtotal hysterectomy (STH) preserves the cervix while removing the upper part of the uterus

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age\>18 years
* Signed informed consent

Exclusion Criteria

* Uterine or adnexal pathology suspect for malignancy
* Abnormal or unknown PAP test
* Patients with invasive neoplasia in the previous 5 years (excluding non-melanoma skin tumors, breast cancer T1 N0 M0 Grade 1 or 2 without signs of recurrence or activity).
* Previous radical pelvic surgery or radiotherapy;
* Age \> 80 years
* Pregnant patients
* Desire for further pregnancies
* Contraindications to general anaesthesia or to the Trendelenburg position
* Refusal to sign informed consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Giovanni Panico, MD

Role: PRINCIPAL_INVESTIGATOR

Fondazione Policlinico Universitario A. Gemelli, IRCCS

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC Ginecologia Oncologica

Rome, Lazio, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Giovanni Panico, MD

Role: CONTACT

+390630153567

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Giovanni Panico, MD

Role: primary

+390630153567

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

6429

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.